Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.

[1]  Publisher Dr. Kumar Ns.  International Journal of Pharmaceutical Sciences Review and Research , 2013 .

[2]  M. Zeegers,et al.  The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. , 2010, Ophthalmology.

[3]  D. Pożarowska.  Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension , 2010, Clinical ophthalmology.

[4]  A. Hommer.  A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. , 2010, Drugs of today.

[5]  C. Lines,et al.  Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  M. Aihara.  Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension , 2010, Clinical ophthalmology.

[7]  H. Uusitalo,et al.  A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[8]  Elizabeth E. Kim,et al.  Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. , 2010, Archives of ophthalmology.

[9]  H. Uusitalo,et al.  Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study , 2010, Acta ophthalmologica.

[10]  T. Hamacher,et al.  Switching from a preserved to a preservative‐free prostaglandin preparation in topical glaucoma medication , 2009, Acta ophthalmologica.

[11]  R. Nema,et al.  TIMOLOL MALEATE A GOLD STANDARD DRUG IN GLAUCOMA USED AS OCULAR FILMS AND INSERTS: AN OVERVIEW , 2010 .

[12]  M. Curran.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. , 2009, Drugs & aging.

[13]  Ciro Costagliola,et al.  Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides , 2009, Expert opinion on pharmacotherapy.

[14]  Ciro Costagliola,et al.  Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics , 2009, Expert opinion on pharmacotherapy.

[15]  L. Bielory,et al.  Allergy to ophthalmic preservatives , 2009, Current opinion in allergy and clinical immunology.

[16]  Jin-wei Cheng,et al.  Systematic Review of Intraocular Pressure-Lowering Effects of Adjunctive Medications Added to Latanoprost , 2009, Ophthalmic Research.

[17]  A. Ropo,et al.  Adjunctive Use of Tafluprost with Timolol Provides Additive Effects for Reduction of Intraocular Pressure in Patients with Glaucoma , 2009, European journal of ophthalmology.

[18]  A. Konstas,et al.  A review of additivity to prostaglandin analogs: fixed and unfixed combinations. , 2008, Survey of ophthalmology.

[19]  C. Baudouin.  Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma , 2008, Acta ophthalmologica.

[20]  A. Alm,et al.  Side effects associated with prostaglandin analog therapy. , 2008, Survey of ophthalmology.

[21]  P. Kaufman,et al.  Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. , 2008, Survey of ophthalmology.

[22]  T. Hamacher,et al.  Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis , 2008, Acta ophthalmologica. Supplement.

[23]  H. Uusitalo,et al.  Pharmacokinetics, efficacy and safety profiles of preserved and preservative‐free tafluprost in healthy volunteers , 2008, Acta ophthalmologica. Supplement.

[24]  Fred Hendrikse,et al.  Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. , 2005, Ophthalmology.

[25]  A. Konstas,et al.  Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma , 2004, Eye.

[26]  M. Kageyama,et al.  Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. , 2004, Experimental eye research.

[27]  R. Parrish,et al.  A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. , 2003, American journal of ophthalmology.

[28]  R. Susanna,et al.  Current status of prostaglandin therapy: latanoprost and unoprostone. , 2002, Survey of ophthalmology.

[29]  J. Whitson.  Travoprost – a new prostaglandin analogue for the treatment of glaucoma , 2002, Expert opinion on pharmacotherapy.

[30]  C. Baudouin,et al.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication , 2002, The British journal of ophthalmology.

[31]  Sanjay S. Patel,et al.  Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. , 1996, Drugs & aging.

[32]  M. Araie,et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. , 1996, Archives of ophthalmology.

[33]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[34]  N. Burstein.  Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. , 1980, Survey of ophthalmology.